[{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2025-02-25T13:39:22.892Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-21"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"5cbe18a7-53bc-4741-8463-14864cc423d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013423","created_at":"2023-08-28T14:08:26.842Z","updated_at":"2025-02-25T17:32:18.916Z","phase":"Phase 2","brief_title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","source_id_and_acronym":"NCT06013423","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 10/31/2031","primary_completion_date":" 10/31/2031","study_txt":" Completion: 10/31/2032","study_completion_date":" 10/31/2032","last_update_posted":"2025-01-31"},{"id":"fd746a04-cf2a-4fe6-8ac1-71be01980b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016806","created_at":"2021-01-18T14:50:46.648Z","updated_at":"2025-02-25T14:14:55.178Z","phase":"Phase 1","brief_title":"Umbilical Cord Blood Transplantation From Unrelated Donors","source_id_and_acronym":"NCT03016806","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-08-19"},{"id":"34e695f6-dbe3-425d-b9ce-de960e381284","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644016","created_at":"2021-01-19T20:39:14.570Z","updated_at":"2024-07-02T16:35:01.196Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","source_id_and_acronym":"NCT04644016","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-05-24"},{"id":"66017a7e-e1f3-43a3-a59a-3c773b2ee231","acronym":"AUGMENT-101","url":"https://clinicaltrials.gov/study/NCT04065399","created_at":"2021-01-18T19:55:07.775Z","updated_at":"2024-07-02T16:35:03.156Z","phase":"Phase 1/2","brief_title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04065399 - AUGMENT-101","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" KMT2A • NUP98","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement","tags":["KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Revuforj (revumenib) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-17"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"9f272c5e-b3bc-4746-bc47-098aa2fc3e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05884333","created_at":"2023-06-01T14:08:00.739Z","updated_at":"2024-07-02T16:35:06.471Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Adults With Blood Cancers","source_id_and_acronym":"NCT05884333","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 05/22/2028","primary_completion_date":" 05/22/2028","study_txt":" Completion: 05/22/2028","study_completion_date":" 05/22/2028","last_update_posted":"2024-05-02"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"be1b1cbc-6baf-4848-9f92-082e2b4cd6b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01203722","created_at":"2021-01-18T04:49:23.205Z","updated_at":"2024-07-02T16:35:15.050Z","phase":"Phase 1/2","brief_title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","source_id_and_acronym":"NCT01203722","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-13"},{"id":"43b99dac-6097-46d8-a900-4109c55cc2e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03434730","created_at":"2021-01-18T16:56:32.937Z","updated_at":"2024-07-02T16:35:16.606Z","phase":"Phase 2","brief_title":"Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation","source_id_and_acronym":"NCT03434730","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • cyclosporine • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2024-03-04"},{"id":"67197a8d-9a9a-4c72-90a0-5288f05dfc03","acronym":"","url":"https://clinicaltrials.gov/study/NCT00357565","created_at":"2021-01-18T01:14:22.260Z","updated_at":"2024-07-02T16:35:22.043Z","phase":"Phase 2","brief_title":"Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia","source_id_and_acronym":"NCT00357565","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-26"},{"id":"2050fa15-b6d6-4b60-b865-2428d62f1a6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01092026","created_at":"2021-01-18T04:18:55.825Z","updated_at":"2024-07-02T16:35:26.947Z","phase":"","brief_title":"Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells","source_id_and_acronym":"NCT01092026","lead_sponsor":"Universitair Ziekenhuis Brussel","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2023-12-06"},{"id":"20bb3a60-35cb-4903-9d63-a1cf0ddca8cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01962636","created_at":"2021-01-18T08:55:07.216Z","updated_at":"2024-07-02T16:35:30.509Z","phase":"","brief_title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","source_id_and_acronym":"NCT01962636","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-03"},{"id":"171e6e7a-7ae1-4fff-874f-6cb21a0b852f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701295","created_at":"2021-01-18T18:08:24.523Z","updated_at":"2024-07-02T16:35:32.967Z","phase":"Phase 1/2","brief_title":"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement","source_id_and_acronym":"NCT03701295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2 • KMT2A • HOXA9 • MEIS1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["IDH1 • IDH2 • KMT2A • HOXA9 • MEIS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pinometostat (EPZ-5676)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 03/06/2020","start_date":" 03/06/2020","primary_txt":" Primary completion: 12/08/2020","primary_completion_date":" 12/08/2020","study_txt":" Completion: 01/12/2021","study_completion_date":" 01/12/2021","last_update_posted":"2023-10-18"},{"id":"147be330-c08c-4ed4-9d27-7e0355b313e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02661035","created_at":"2021-01-18T12:57:57.203Z","updated_at":"2024-07-02T16:35:36.183Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC for Hematological Diseases","source_id_and_acronym":"NCT02661035","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 03/09/2017","start_date":" 03/09/2017","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 05/29/2023","study_completion_date":" 05/29/2023","last_update_posted":"2023-09-21"},{"id":"1ec7ade3-a1ff-44d4-b7ca-e3d08c57d7b8","acronym":"IM-TMI","url":"https://clinicaltrials.gov/study/NCT04187105","created_at":"2021-01-18T20:24:37.787Z","updated_at":"2024-07-02T16:35:37.511Z","phase":"Phase 2","brief_title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","source_id_and_acronym":"NCT04187105 - IM-TMI","lead_sponsor":"University of Illinois at Chicago","biomarkers":" RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)","tags":["RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-09-11"},{"id":"55ae7010-7764-4de2-8cd8-29528a06d55c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03121014","created_at":"2021-01-18T15:22:34.706Z","updated_at":"2024-07-02T16:35:44.013Z","phase":"Phase 2","brief_title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","source_id_and_acronym":"NCT03121014","lead_sponsor":"University of Illinois at Chicago","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 04/24/2024","primary_completion_date":" 04/24/2024","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2023-07-04"},{"id":"9a7a55eb-f203-4d96-9658-dfd013c067a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005585","created_at":"2023-04-06T19:03:10.305Z","updated_at":"2024-07-02T16:35:51.229Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00005585","lead_sponsor":"Children's Oncology Group","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Kidrolase (L-asparaginase)"],"overall_status":"Completed","enrollment":" Enrollment 838","initiation":"Initiation: 04/01/2000","start_date":" 04/01/2000","primary_txt":" Primary completion: 07/01/2007","primary_completion_date":" 07/01/2007","study_txt":"","study_completion_date":"","last_update_posted":"2023-04-06"},{"id":"e1c7ba24-44af-4b89-9a62-1500c297696f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02722668","created_at":"2021-01-18T13:19:16.731Z","updated_at":"2024-07-02T16:35:54.803Z","phase":"Phase 2","brief_title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","source_id_and_acronym":"NCT02722668","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-02-24"},{"id":"c90517ed-4cab-47f7-b809-cd92d7ae59c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00739141","created_at":"2021-01-18T02:47:22.078Z","updated_at":"2024-07-02T16:35:59.406Z","phase":"Phase 2","brief_title":"Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.","source_id_and_acronym":"NCT00739141","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/12/2008","start_date":" 08/12/2008","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2022-12-08"},{"id":"8f85763f-e649-4c88-96b6-c0ae0f05eac2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744223","created_at":"2021-01-18T07:37:40.124Z","updated_at":"2024-07-02T16:36:07.432Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","source_id_and_acronym":"NCT01744223","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 10/09/2019","primary_completion_date":" 10/09/2019","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2022-07-12"},{"id":"89d88dc2-c1e4-4a45-b7f0-527d8736891a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01597778","created_at":"2021-01-18T06:49:49.857Z","updated_at":"2024-07-02T16:36:19.976Z","phase":"Phase 3","brief_title":"Double Cord Versus Haploidentical (BMT CTN 1101)","source_id_and_acronym":"NCT01597778","lead_sponsor":"Medical College of Wisconsin","biomarkers":" NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 368","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 09/11/2020","primary_completion_date":" 09/11/2020","study_txt":" Completion: 09/11/2020","study_completion_date":" 09/11/2020","last_update_posted":"2021-12-01"},{"id":"a6742da7-4f7d-4b8b-afbd-b3501d99164e","acronym":"HaploOnly","url":"https://clinicaltrials.gov/study/NCT02660281","created_at":"2021-01-18T12:57:44.580Z","updated_at":"2024-07-02T16:36:21.515Z","phase":"Phase 1","brief_title":"URMC Related Haplo-identical Donor BMT","source_id_and_acronym":"NCT02660281 - HaploOnly","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/28/2019","primary_completion_date":" 10/28/2019","study_txt":" Completion: 01/07/2021","study_completion_date":" 01/07/2021","last_update_posted":"2021-11-03"}]